How to Treat EGFR-Mutated Non-Small Cell Lung Cancer

被引：4
|
作者：
Belani, Neel [1 ,4 ]
Liang, Katherine [2 ]
Fradley, Michael [3 ]
Judd, Julia [1 ]
Borghaei, Hossein [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA USA
[2] Temple Univ Hlth Syst, Dept Internal Med, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Cardiooncol Translat Ctr Excellence, Div Cardiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, 333 Cotman Ave, Philadelphia, PA 19111 USA
来源：
JACC: CARDIOONCOLOGY | 2023年 / 5卷 / 04期
关键词：
cardiomyopathy; lung cancer; tyrosine kinase inhibitor; OSIMERTINIB;
D O I：
10.1016/j.jaccao.2023.04.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：542 / 545
页数：4
相关论文
共 50 条
  • [41] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [42] EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
    Madeddu, Clelia
    Donisi, Clelia
    Liscia, Nicole
    Lai, Eleonora
    Scartozzi, Mario
    Maccio, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [43] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
  • [44] TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China
    Wang, Han
    Ma, Junrui
    Lu, Jiagui
    Wang, Yang
    Zhang, Binli
    Zhang, Hushan
    Peng, Hao
    BIOMARKERS IN MEDICINE, 2024, 18 (24) : 1123 - 1133
  • [45] Estrogen Metabolism in Patients with EGFR-Mutated and ALK-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Bodor, J. N.
    Treat, J.
    Krzizike, D. D.
    Zawislak, C. L.
    Vanderveer, L.
    Yulis, M.
    Chau, A.
    Ross, E. A.
    Andrews, A. J.
    Clapper, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S18 - S19
  • [46] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [47] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [48] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [49] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [50] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
    Di Marino, Pietro
    Chiapperino, Cosima
    Primavera, Francesca Chiara
    Martino, Maria Teresa
    Brocco, Davide
    Carella, Consiglia
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    ONCOTARGETS AND THERAPY, 2022, 15 : 407 - 410
12345